Prognostic value of central venous-to-arterial carbon dioxide difference in patients with bloodstream infection

Background: Bloodstream infection (BSI) are prone to circulation disorders, which portend poor outcome. The central venous-to-arterial carbon dioxide difference (Pcv-aCO₂) is a biomarker for circulation disorders, but the prognostic value of Pcv-aCO₂ in BSI patients remains unclear. This study was to investigate the association of Pcv-aCO₂ with adverse events in BSI patients.Methods: The patients with BSI between August 2014 and August 2017 were prospectively enrolled. Clinical characteristic and laboratory results were collected. We analyzed the association of the level of Pcv-aCO₂ with clinical variables and 28-day mortality.Results: A total of 152 patients were enrolled. The Pcv-aCO₂ was positively correlated with white blood cell count (r=0.241, p=0.003), procalcitonin (r=0.471, p<0.001), C-reactive protein (r=0.192, p=0.018), lactate (r=0.179, p=0.027), Sequential Organ Failure Assessment (r=0.318, p<0.001) and Acute Physiology And Chronic Health Evaluation II score (r=0.377, p<0.001), while that was negatively correlated with central venous oxygen saturation (r=-0.242, p<0.001) and platelet (r=-0.205, p=0.011). Kaplan-Meier curves demonstrated that patients with Pcv-aCO₂ >6mmHg had a worse prognosis than those without (log rank=32.10, p<0.001). Multivariate analysis showed Level of Pcv-aCO₂ was an independent risk factor for 28-day mortality (HR: 3.10, 95% CI: 1.43-6.74, p=0.004). The area under the receiver operating characteristic curve of Pcv-aCO₂ for prediction of 28-day mortality in patients with BSI was 0.794. Pcv-aCO₂>6 mmHg had 81.1% sensitivity and 78.8% specificity for predicting 28-day mortality.Conclusion: Pcv-aCO₂ may be a simple and valuable biomarker to assessment of 28-day mortality in patients with BSI.